SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is trending as investors weigh the company's decision to slow development on its Reko Diq project in Pakistan due to regional security risks, sparking debate over capital expenditure and long-term project viability. The community is actively discussing the stock's valuation and strategic outlook as they balance potential for future production against ongoing geopolitical headwinds.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing heightened investor interest and increased volume as the community monitors its performance ahead of an earnings report that analysts expect to be a major catalyst. Market participants are actively debating the potential for a breakout, driven by the company's backlog expansion and competitive positioning in the space launch sector, even as some traders remain cautious regarding volatility surrounding broader sector trends.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors closely monitor the critical 80th event milestone in the REGAL Phase 3 trial, with mounting speculation regarding institutional accumulation and a potential lucrative buyout. The community remains divided between intense bullish sentiment focused on the stock's role as a groundbreaking oncology platform and bearish concerns over trial timelines and clinical execution.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is currently trending as investors debate the impact of broader space-sector volatility following recent IPO activity and recurring institutional interest from major tech firms. While some community members express frustration over recent price corrections and equity offerings, others remain focused on the company's long-term geospatial data backlog and its integration into evolving AI and defense infrastructure.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending as investors aggressively position themselves ahead of the upcoming Phase 2 top-line data readout for ABCL635, a key milestone that the community views as a major clinical validation for the company's AI-driven drug discovery platform. Market participants are intensely debating the stock's potential for a short squeeze and long-term re-rating, fueled by recent institutional accumulation and high-profile pharmaceutical partnerships that have sparked significant speculative volume.

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

Doximity Inc

Doximity shares are experiencing extreme volatility and heavy volume following an earnings report that highlighted a pivot toward clinical AI, triggering a massive short squeeze despite mixed financial results. The community remains sharply divided, with bulls pointing to the company's proprietary data and AI-driven outlook, while bears characterize the surge as a manipulative pump-and-dump scheme ripe for a correction.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors debate the potential implications of a rumored acquisition of eBay, while discussions continue around share dilution and institutional accumulation. The community remains heavily polarized, with many looking for signs of a short squeeze while others express frustration over stagnant price action.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending as investors actively discuss its transition from a Bitcoin miner to a high-performance AI infrastructure provider, fueled by significant new long-term data center lease agreements. The community is heavily focused on the stock's recent bullish momentum, analyst upgrades, and the strategic pivot that is positioning the company to capture surging demand for power and data center capacity.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO Inc. is trending as investors debate the stock's potential for a major reversal, driven by anticipation of upcoming earnings and recent institutional activity. Community discussion is heavily focused on the company's long-term integration strategy, the impact of high-interest rates, and aggressive short-selling activity that has created significant volatility.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang continues to drive global interest as it advances toward mass commercialization, recently hitting major milestones like the pilotless EH216-S flight in Kazakhstan and securing an institutional stake from Fidelity. Community sentiment remains focused on the company's tangible progress in international regulatory sandboxes and the potential for a massive upside as the autonomous eVTOL sector prepares to scale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VERU opus 5 on veru ranking as bolt on acquisition  
 
Ranked on cost, probability, and existing Novo relationships — with ZEUS failure properly weighted: 
 
1. Veru — Cheapest by two orders of magnitude (~$50M; $100–250M taken out).  
 
2. MBX Biosciences — Matches Novo’s reported monthly-GLP-1 interest 
 
3. Fulcrum — Cheap, sits in Novo’s established rare-blood franchise 
 
4. Ventus Therapeutics — Still the only name already inside Novo’s pipeline 
 
5. Agios — Best de-risked asset on the list (approved product, right franchise). Weakness: upper-bolt-on price 
 
6. BioAge Labs — Scientifically the most interesting 
 
7. XORTX — Very cheap, renal adjacency. Weakness: no relationship, no signal, minimal visibility. 
 
8. Vasa — Bolt-on cost, HFpEF fits post-ZEUS CV needs. Weakness: very early, and its tie is to Lilly. 
 
9. Zealand Pharma — Strategically the most attractive assets

Sébastien Charbonneau

cray1965

StockTwits Web

Veru Inc

 opus 5 on veru ranking as bolt on acquisition  
 
Ranked on cost, probability, and existing Novo relationships — with ZEUS failure properly weighted: 
 
1. Veru — Cheapest by two orders of magnitude (~$50M; $100–250M taken out).  
 
2. MBX Biosciences — Matches Novo’s reported monthly-GLP-1 interest 
 
3. Fulcrum — Cheap, sits in Novo’s established rare-blood franchise 
 
4. Ventus Therapeutics — Still the only name already inside Novo’s pipeline 
 
5. Agios — Best de-risked asset on the list (approved product, right franchise). Weakness: upper-bolt-on price 
 
6. BioAge Labs — Scientifically the most interesting 
 
7. XORTX — Very cheap, renal adjacency. Weakness: no relationship, no signal, minimal visibility. 
 
8. Vasa — Bolt-on cost, HFpEF fits post-ZEUS CV needs. Weakness: very early, and its tie is to Lilly. 
 
9. Zealand Pharma — Strategically the most attractive assets